Business Wire

Boston BioProducts Receives ISO 13485:2016 Quality Certification

6.4.2023 16:03:00 EEST | Business Wire | Press release

Share

Boston BioProducts, a longstanding manufacturer of fundamental reagents for the life sciences, today announced that its quality management system (QMS) has achieved ISO 13485:2016 certification from TÜV SÜD America for the medical device manufacturing and supply of buffers, solutions, media, and reagents serving research, diagnostics, and therapeutics applications. Achieving this certification signifies Boston BioProducts’ commitment to high-quality standards across the entire reagent manufacturing process.

ISO 13485:2016 is considered the industry standard for QMS systems designed for medical devices and related services. It sets a robust and reproducible framework for the design, development, and manufacturing of products that meets customer and regulatory requirements. The International Organization for Standardization (ISO) is a global, independent publisher of standards governing the safety, reliability, and quality of manufactured products. TÜV SÜD America is among the most respected and accomplished certification bodies in the market serving thousands of registrations worldwide.

“This major company milestone further supports Boston BioProducts’ path to becoming a premier partner for contract reagent development and manufacturing across research, diagnostics, and therapeutics”, said Neil Sharma, General Manager of Boston BioProducts. “Scientists, assay developers, and manufacturing engineers can rely on a single source for the customization, testing, and supply of their process-critical buffers, solutions, and media reagents whether starting from innovation to publication, RUO to IVD, or preclinical to GMP.”

With the ISO 13485:2016 certification, Boston BioProducts is better positioned to support a range of growing regulated applications such as in vitro diagnostics, clinical trial assays , and cell and gene therapy manufacturing. This elevated quality management system complements the company’s flexible custom reagent manufacturing and rapid product delivery.

About Boston BioProducts

For nearly 30 years, Boston BioProducts (BBP) has manufactured and supplied fundamental reagents (buffers, solutions, media, and more) to researchers, diagnostic and technology platforms, and drug developers worldwide. With its custom reagent manufacturing services, BBP becomes an extension of your lab with flexible parameters to design the ideal research and manufacturing tools. Its mission is to increase the reproducibility of product- and process-critical reagents that keep your science consistent and moving forward. For more information, please visit www.bostonbioproducts.com and follow us on LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Boston BioProducts Marketing
marketing@bostonbioproducts.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Textron Aviation Announces Fleet Order From LUMINAIR to Operate Nine Best-selling Cessna Citation Latitude Midsize Business Jets, Supporting Charter Operations Across Europe21.4.2026 14:42:00 EEST | Press release

Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, today announced at AERO Friedrichshafen it has entered into a purchase agreement with LUMINAIR, a private jet operator in Europe, to operate nine Cessna Citation Latitude business jets. Renowned for its exceptional features, versatility, impressive range and operating economics, the best-selling midsize business jet was selected by LUMINAIR to support their increasing demand and enhance their mission flexibility. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420434515/en/ Textron Aviation announces fleet order from LUMINAIR to operate nine best-selling Cessna Citation Latitude midsize business jets, supporting charter operations across Europe. (Photo credit: Textron Aviation) “The Citation Latitude is exceptionally well suited to LUMINAIR customers travelling across Europe, offering a spacious and comfortable cabin experience along with the reliability they need t

Textron Aviation Announces Fleet Order From LUMINAIR to Operate Nine Best-selling Cessna Citation Latitude Midsize Business Jets, Supporting Charter Operations Across Europe21.4.2026 14:42:00 EEST | Press release

Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, today announced at AERO Friedrichshafen it has entered into a purchase agreement with LUMINAIR, a private jet operator in Europe, to operate nine Cessna Citation Latitude business jets. Renowned for its exceptional features, versatility, impressive range and operating economics, the best-selling midsize business jet was selected by LUMINAIR to support their increasing demand and enhance their mission flexibility. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420434515/en/ Textron Aviation announces fleet order from LUMINAIR to operate nine best-selling Cessna Citation Latitude midsize business jets, supporting charter operations across Europe. (Photo credit: Textron Aviation) “The Citation Latitude is exceptionally well suited to LUMINAIR customers travelling across Europe, offering a spacious and comfortable cabin experience along with the reliability they need t

The smarter E Europe: The Special Exhibit Renewables 24/7 Shows How a Renewable Energy Supply Is Possible21.4.2026 14:00:00 EEST | Press release

The current geopolitical situation once again highlights the risks of depending on fossil fuels and the increasing need to transform our energy supply. Solar and wind power have long been established as cost-efficient energy sources, and the International Energy Agency (IEA) has predicted a global 2.6-fold capacity growth between 2022 and 2030. Against this backdrop, The smarter E Europe alliance of exhibitions will spotlight the feasibility of a renewable energy system from June 23–25 in Munich. The Special Exhibit Renewables 24/7 uses best practices, presentations and live demos to show how a round-the-clock renewable energy supply can be achieved. To kick off the exhibition on June 23, The smarter E Europe will present an exclusive accompanying study, conducted in collaboration with the Fraunhofer Institute for Solar Energy Systems, that dispels common myths about system stability and provides scientific proof that such an energy system is viable. The study, Pathways to a Renewable

The smarter E Europe: The Special Exhibit Renewables 24/7 Shows How a Renewable Energy Supply Is Possible21.4.2026 14:00:00 EEST | Press release

The current geopolitical situation once again highlights the risks of depending on fossil fuels and the increasing need to transform our energy supply. Solar and wind power have long been established as cost-efficient energy sources, and the International Energy Agency (IEA) has predicted a global 2.6-fold capacity growth between 2022 and 2030. Against this backdrop, The smarter E Europe alliance of exhibitions will spotlight the feasibility of a renewable energy system from June 23–25 in Munich. The Special Exhibit Renewables 24/7 uses best practices, presentations and live demos to show how a round-the-clock renewable energy supply can be achieved. To kick off the exhibition on June 23, The smarter E Europe will present an exclusive accompanying study, conducted in collaboration with the Fraunhofer Institute for Solar Energy Systems, that dispels common myths about system stability and provides scientific proof that such an energy system is viable. The study, Pathways to a Renewable

Compass Pathways Collaborates with Osmind to Advance Independent Clinic Readiness for Psychedelic Treatments21.4.2026 13:30:00 EEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it has entered into a collaboration with Osmind, the platform powering a nationwide network of interventional psychiatry practices. This collaboration will inform how small-to-medium sized clinics nationwide can effectively deliver novel psychedelic treatments, if FDA approved. The agreement with Osmind further expands the set of collaborations that Compass has established to inform the potential delivery of COMP360 in a broad spectrum of settings where people living with mental health conditions receive their care in the United States. Osmind is a public benefit corporation advancing psychiatry through technology, services, and real-world evidence to bring innovative mental health treatments to patients in need. Osmind’s network of over 1,000 clinics comprises one of the country’s largest network of interventional psychiatry practices. Its

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye